retatrutide obesity trial results Results: 28.3% Weight Loss Data RETATRUTIDE! The new magic for

A drug with 28% mean weight loss can have very different commercial and clinical profiles depending on whether that mean is produced by a narrow cluster of super-responders or by broad consistent response across the enrolled population

Evidence for MAIT cell activity in MASH is limited and inconclusive

Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, et al

Eli Lilly (LLY -2.39%) received approval for Zepbound, a weight-management medicine, in November 2023

Interest accrues from day one

Injection site management Given the elevated injection site reaction rates with cagrilintide, proactive management is especially important: Rotate injection sites systematically using a rotation schedule (abdomen, right thigh, left thigh, right arm, left arm) Allow the solution to reach room temperature before injecting Inject slowly over 5 to 10 seconds rather than quickly Apply ice before injection to reduce pain Do not massage the injection site afterward Use proper technique as outlined in our peptide injection guide Keeping a log of injection sites and reactions helps identify whether certain areas are more problematic than others